Nifty
Sensex
:
:
11419.25
38337.01
-177.65 (-1.53%)
-560.45 (-1.44%)

Pharmaceuticals & Drugs

Rating :
60/99  (View)

BSE: 500124 | NSE: DRREDDY

2613.15
-42.40 (-1.60%)
19-Jul-2019 | 3:56PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  2659.95
  •  2680.00
  •  2604.05
  •  2655.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  468248
  •  12236.02
  •  2964.00
  •  1872.95

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 44,111.53
  • 22.62
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 47,003.40
  • 0.77%
  • 3.16

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.77%
  • 3.45%
  • 7.85%
  • FII
  • DII
  • Others
  • 0.21%
  • 14.03%
  • 47.69%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.26
  • 0.56
  • 2.86

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.35
  • -1.87
  • 5.15

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.42
  • -3.99
  • 14.88

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.06
  • 28.44
  • 33.35

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.68
  • 4.24
  • 3.42

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.77
  • 17.59
  • 17.11

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
4,029.60
3,553.90
13.39%
3,864.60
3,834.10
0.80%
3,817.50
3,559.80
7.24%
3,736.50
3,333.20
12.10%
Expenses
3,210.70
2,990.30
7.37%
3,060.00
3,041.40
0.61%
3,058.20
2,890.40
5.81%
2,967.70
3,010.00
-1.41%
EBITDA
818.90
563.60
45.30%
804.60
792.70
1.50%
759.30
669.40
13.43%
768.80
323.20
137.87%
EBIDTM
20.32%
15.86%
20.82%
20.68%
19.89%
18.80%
20.58%
9.70%
Other Income
83.30
44.90
85.52%
102.30
43.00
137.91%
128.20
31.60
305.70%
50.40
38.00
32.63%
Interest
24.50
17.80
37.64%
24.10
17.20
40.12%
20.80
22.30
-6.73%
19.50
21.50
-9.30%
Depreciation
287.20
276.30
3.94%
290.30
271.50
6.92%
278.60
270.20
3.11%
278.70
259.20
7.52%
PBT
590.50
314.40
87.82%
592.50
547.00
8.32%
588.10
408.50
43.97%
521.00
80.50
547.20%
Tax
150.80
49.20
206.50%
101.10
252.80
-60.01%
80.70
112.30
-28.14%
53.20
23.70
124.47%
PAT
439.70
265.20
65.80%
491.40
294.20
67.03%
507.40
296.20
71.30%
467.80
56.80
723.59%
PATM
10.91%
7.46%
12.72%
7.67%
13.29%
8.32%
12.52%
1.70%
EPS
27.43
16.39
67.36%
30.14
18.26
65.06%
31.22
18.42
69.49%
28.68
4.02
613.43%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
-
15,448.20
14,281.00
14,196.10
15,568.30
15,023.30
13,415.30
11,895.60
9,814.50
7,496.90
6,988.60
Net Sales Growth
-
8.17%
0.60%
-8.81%
3.63%
11.99%
12.78%
21.20%
30.91%
7.27%
 
Cost Of Goods Sold
-
4,494.80
4,039.50
3,696.50
3,758.50
3,786.40
3,317.10
3,516.80
2,568.30
2,091.10
2,061.70
Gross Profit
-
10,953.40
10,241.50
10,499.60
11,809.80
11,236.90
10,098.20
8,378.80
7,246.20
5,405.80
4,926.90
GP Margin
-
70.90%
71.71%
73.96%
75.86%
74.80%
75.27%
70.44%
73.83%
72.11%
70.50%
Total Expenditure
-
12,270.00
11,929.80
11,723.90
11,983.00
11,529.70
10,164.70
9,176.10
7,374.90
5,936.00
5,563.50
Power & Fuel Cost
-
329.10
329.30
330.10
315.20
339.10
319.90
335.40
225.90
183.30
141.50
% Of Sales
-
2.13%
2.31%
2.33%
2.02%
2.26%
2.38%
2.82%
2.30%
2.45%
2.02%
Employee Cost
-
3,356.20
3,214.90
3,106.80
3,117.40
2,944.60
2,475.40
1,928.70
1,591.20
1,304.80
1,183.20
% Of Sales
-
21.73%
22.51%
21.88%
20.02%
19.60%
18.45%
16.21%
16.21%
17.40%
16.93%
Manufacturing Exp.
-
1,434.80
1,746.50
1,886.60
1,856.40
1,999.10
1,747.60
1,441.30
1,237.00
985.90
921.80
% Of Sales
-
9.29%
12.23%
13.29%
11.92%
13.31%
13.03%
12.12%
12.60%
13.15%
13.19%
General & Admin Exp.
-
1,143.70
1,198.90
1,339.90
1,271.40
1,037.30
1,004.30
796.30
682.90
479.00
413.50
% Of Sales
-
7.40%
8.40%
9.44%
8.17%
6.90%
7.49%
6.69%
6.96%
6.39%
5.92%
Selling & Distn. Exp.
-
1,423.50
1,330.20
1,293.40
1,181.10
1,357.50
1,264.80
1,119.10
984.40
744.90
691.00
% Of Sales
-
9.21%
9.31%
9.11%
7.59%
9.04%
9.43%
9.41%
10.03%
9.94%
9.89%
Miscellaneous Exp.
-
87.90
70.50
70.60
483.00
65.70
35.60
38.50
85.20
147.00
691.00
% Of Sales
-
0.57%
0.49%
0.50%
3.10%
0.44%
0.27%
0.32%
0.87%
1.96%
2.16%
EBITDA
-
3,178.20
2,351.20
2,472.20
3,585.30
3,493.60
3,250.60
2,719.50
2,439.60
1,560.90
1,425.10
EBITDA Margin
-
20.57%
16.46%
17.41%
23.03%
23.25%
24.23%
22.86%
24.86%
20.82%
20.39%
Other Income
-
337.50
155.20
171.50
295.00
274.10
169.90
149.90
132.30
52.30
103.10
Interest
-
88.90
78.80
63.40
82.60
108.20
126.70
100.30
114.10
32.30
38.50
Depreciation
-
1,134.80
1,077.20
1,026.60
938.90
759.90
647.50
550.20
518.10
398.10
413.10
PBT
-
2,292.00
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,218.90
1,939.70
1,182.80
1,076.60
Tax
-
385.80
438.00
296.50
751.10
563.20
683.10
637.90
503.50
183.90
266.80
Tax Rate
-
16.83%
32.43%
19.08%
26.27%
19.42%
25.81%
29.47%
27.90%
15.55%
43.15%
PAT
-
1,906.20
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
PAT before Minority Interest
-
1,906.20
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
Minority Interest
-
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-
12.34%
6.39%
8.86%
13.54%
15.55%
14.63%
12.83%
13.25%
13.32%
5.03%
PAT Growth
-
108.92%
-27.43%
-40.35%
-9.79%
19.01%
28.58%
17.36%
30.23%
184.18%
 
Unadjusted EPS
-
117.53
57.08
77.53
124.93
137.18
115.45
89.93
76.76
59.06
20.83

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
14,023.60
12,571.60
12,262.10
12,569.80
9,853.10
7,865.20
6,369.10
4,989.00
4,031.90
3,776.80
Share Capital
83.00
83.00
82.90
85.30
85.20
85.10
84.90
84.80
84.60
84.40
Total Reserves
13,861.10
12,406.00
12,098.80
12,393.90
9,677.40
7,698.60
6,215.30
4,849.10
3,906.80
3,657.40
Non-Current Liabilities
2,113.00
2,538.40
456.10
876.70
1,678.40
2,182.30
1,285.10
1,609.80
600.30
1,491.00
Secured Loans
55.20
63.00
59.70
74.70
77.50
94.70
80.20
26.10
24.40
26.90
Unsecured Loans
2,144.80
2,445.90
485.20
993.80
1,354.00
1,980.80
1,185.70
1,615.80
512.80
1,457.10
Long Term Provisions
79.30
81.70
84.20
95.20
77.90
56.30
51.40
33.30
28.80
0.00
Current Liabilities
5,897.30
6,893.80
8,419.90
6,347.10
6,821.30
5,790.40
5,658.80
4,591.40
4,208.50
2,024.80
Trade Payables
1,367.10
1,334.50
1,056.90
906.80
867.30
893.20
965.70
756.60
634.50
1,667.90
Other Current Liabilities
2,820.70
2,411.40
2,339.70
2,409.10
2,624.40
2,020.80
2,120.40
1,749.20
1,328.90
6.70
Short Term Borrowings
1,212.50
2,556.20
4,362.60
2,271.80
2,185.70
2,060.70
1,898.60
1,588.80
1,831.90
0.00
Short Term Provisions
497.00
591.70
660.70
759.40
1,143.90
815.70
674.10
496.80
413.20
350.20
Total Liabilities
22,033.90
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
Net Block
7,191.00
6,968.00
6,930.70
6,563.00
5,377.00
4,640.80
4,050.60
3,411.70
3,385.50
2,352.20
Gross Block
18,048.40
17,436.30
15,932.40
15,019.70
12,573.60
11,917.60
10,089.40
8,842.30
7,975.10
6,446.80
Accumulated Depreciation
10,845.80
10,463.00
9,001.70
8,456.70
7,169.90
7,276.80
5,984.60
5,295.30
4,589.60
4,094.60
Non Current Assets
10,923.80
11,505.40
11,454.40
7,999.60
6,476.10
5,512.20
4,786.30
4,191.20
4,025.70
3,115.00
Capital Work in Progress
2,933.50
3,470.50
3,324.50
772.20
529.00
638.80
565.30
708.50
575.20
762.20
Non Current Investment
334.20
465.30
682.60
329.70
145.60
0.40
0.40
0.90
0.90
0.60
Long Term Loans & Adv.
426.70
564.80
482.10
290.40
418.10
232.20
149.10
70.10
64.10
0.00
Other Non Current Assets
38.40
36.80
34.50
44.30
6.40
0.00
20.90
0.00
0.00
0.00
Current Assets
11,110.10
10,498.40
9,683.70
11,794.00
11,876.70
10,325.70
8,526.70
6,999.00
4,815.00
4,177.60
Current Investments
2,252.90
1,833.00
1,427.10
3,503.40
2,102.20
1,066.40
196.60
207.00
0.00
357.40
Inventories
3,357.90
2,908.90
2,852.80
2,557.90
2,569.90
2,418.80
2,170.70
1,943.30
1,599.20
1,339.40
Sundry Debtors
3,986.90
4,052.70
3,798.60
4,125.00
4,101.20
3,325.30
3,180.40
2,536.80
1,761.10
1,159.90
Cash & Bank
222.80
263.80
386.50
492.10
1,872.40
2,300.60
2,017.10
1,606.10
575.10
660.00
Other Current Assets
1,289.60
481.70
451.50
393.10
1,231.00
1,214.60
961.90
705.80
879.60
660.90
Short Term Loans & Adv.
439.80
958.30
767.20
722.50
1,004.80
1,044.20
796.90
611.60
763.20
658.70
Net Current Assets
5,212.80
3,604.60
1,263.80
5,446.90
5,055.40
4,535.30
2,867.90
2,407.60
606.50
2,152.80
Total Assets
22,033.90
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
2,870.40
1,803.00
2,144.40
3,262.60
2,523.50
1,969.70
1,377.90
1,612.60
755.40
1,315.00
PBT
2,292.00
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,164.70
1,804.40
1,182.80
618.30
Adjustment
1,639.60
1,625.30
1,687.30
1,107.70
1,654.00
1,042.70
1,062.80
1,157.40
530.10
1,117.30
Changes in Working Capital
-577.10
-896.60
-519.60
-2.50
-1,483.70
-1,005.00
-1,294.40
-893.80
-658.70
-137.50
Cash after chg. in Working capital
3,354.50
2,079.10
2,721.40
3,964.00
3,069.90
2,684.00
1,933.10
2,068.00
1,054.20
1,598.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-484.10
-276.10
-577.00
-701.40
-546.40
-714.30
-555.20
-455.40
-298.80
-283.10
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-772.70
-1,488.30
-1,840.40
-2,039.40
-2,264.70
-1,694.10
-1,446.30
-1,888.40
-898.80
-710.20
Net Fixed Assets
-275.60
-683.20
-1,019.30
-1,892.20
-828.10
-819.60
-530.80
-554.40
-399.90
-602.60
Net Investments
-297.00
-534.60
1,974.20
-1,213.80
-1,055.80
-427.30
98.50
-15.70
93.10
-851.30
Others
-200.10
-270.50
-2,795.30
1,066.60
-380.80
-447.20
-1,014.00
-1,318.30
-592.00
743.70
Cash from Financing Activity
-2,132.60
-444.00
-369.20
-1,700.10
-433.20
-24.20
-156.80
389.10
44.50
-531.70
Net Cash Inflow / Outflow
-34.90
-129.30
-65.20
-476.90
-174.40
251.40
-225.20
113.30
-98.90
73.10
Opening Cash & Equivalents
254.20
377.80
492.10
539.50
862.40
520.40
736.20
573.00
660.00
562.30
Closing Cash & Equivalent
222.80
254.20
377.80
492.10
582.90
862.40
520.40
736.20
575.10
660.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
840.01
752.35
734.72
731.49
572.92
457.33
371.04
290.91
235.90
221.67
ROA
8.66%
4.23%
6.14%
11.05%
13.67%
13.47%
12.46%
12.99%
12.38%
4.82%
ROE
14.42%
7.40%
10.20%
18.95%
26.63%
27.88%
27.18%
29.15%
25.83%
9.72%
ROCE
13.41%
8.21%
9.77%
19.55%
22.69%
24.77%
24.79%
26.24%
20.84%
12.18%
Fixed Asset Turnover
0.87
0.86
0.92
1.13
1.23
1.23
1.26
1.17
1.04
1.09
Receivable days
94.98
100.33
101.86
96.43
89.72
87.97
87.19
79.59
70.77
67.20
Inventory Days
74.03
73.63
69.56
60.11
60.27
62.06
62.74
65.60
71.20
68.85
Payable days
39.46
37.10
31.00
28.67
28.48
33.96
34.99
35.37
72.19
108.29
Cash Conversion Cycle
129.55
136.86
140.42
127.87
121.51
116.06
114.93
109.82
69.78
27.76
Total Debt/Equity
0.28
0.41
0.40
0.27
0.44
0.58
0.58
0.66
0.59
0.40
Interest Cover
26.78
18.14
25.51
35.61
27.80
21.89
22.58
16.81
37.62
17.06

News Update


  • Dr Reddy's Lab launches Fexofenadine HCI, Pseudoephedrine HCI Extended-Release Tablets
    19th Jul 2019, 11:18 AM

    The company’s OTC Fexofenadine HCI 60 mg and Pseudoephedrine HCI 120 mg Extended-Release Tablets, USP are available in 20- and 30-count sizes

    Read More
  • USFDA completes audit at Dr. Reddy’s Laboratories’ Hyderabad plant
    12th Jul 2019, 14:40 PM

    The company has been issued a Form 483 with 5 observations

    Read More
  • Dr Reddy's Lab launches OTC store-brand equivalent of Mucinex D Extended Release Tablets
    9th Jul 2019, 11:41 AM

    The company’s OTC Guaifenesin 1200 mg and Pseudoephedrine HCI 120 mg is available in 24-count packages

    Read More
  • Dr Reddy's Laboratories planning to launch value-added drugs in US
    8th Jul 2019, 11:47 AM

    The company has also planning to re-focus some of its Research and Development resources

    Read More
  • Dr. Reddy's launches Carboprost Tromethamine Injection USP
    3rd Jul 2019, 12:54 PM

    Dr. Reddy's Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) contains carboprost tromethamine equivalent to 250 mcg of carboprost

    Read More
  • Dr. Reddy's Lab launches Tobramycin Inhalation Solution in US market
    25th Jun 2019, 14:17 PM

    The company’s Tobramycin Inhalation Solution, USP is available in a 300 mg/5 ml, single-dose Ampule

    Read More
  • USFDA completes audit at Dr. Reddy’s Laboratories’ Vizag Plants
    24th Jun 2019, 09:53 AM

    The company has been issued a Form 483 with 2 observations

    Read More
  • Dr. Reddy's Lab launches Phytonadione Injectable Emulsion in US
    24th Jun 2019, 09:00 AM

    The Vitamin K1 for Injectable Emulsion USP, 10 mg/ml brand and generic had combined US sales of approximately $46.6 million MAT

    Read More
  • Dr. Reddy's Lab enters into definitive agreement with Upsher-Smith Laboratories, LLC
    14th Jun 2019, 09:39 AM

    Under the agreement, the company will receive $70 million as upfront consideration, $40.5 million in near term milestones

    Read More
  • Dr. Reddy's Lab reports positive topline results from Phase 2b study of PPC-06
    10th Jun 2019, 11:33 AM

    PPC-06 met both co-primary endpoints i.e. PASI- 75 and IGA scores of 0 or 1

    Read More
  • Dr. Reddy's Lab re-launches Zenatane
    4th Jun 2019, 08:59 AM

    The product is being launched with an approved REMS Program

    Read More
  • Dr. Reddy's Lab gets EIR from USFDA for Miryalaguda plant
    31st May 2019, 11:44 AM

    The company has received EIR indicating closure of the audit and the inspection classification of this facility is determined as VAI

    Read More
  • Dr Reddy’s Lab to spend upto $300 million on R&D in FY20
    20th May 2019, 16:32 PM

    The R&D spends for the January-March quarter of FY19 is $53 million

    Read More
  • Dr. Reddy's laboratories reports 66% rise in Q4 consolidated net profit
    17th May 2019, 16:45 PM

    Total consolidated income of the company rose 14.29% at Rs 4,112.90 crore for quarter ended March 31, 2019

    Read More
  • Dr. Reddys Lab - Quarterly Results
    17th May 2019, 15:00 PM

    Read More
  • Dr. Reddy's Lab launches Daptomycin for Injection
    15th May 2019, 10:40 AM

    The Injection is available in single-dose 15 ml vials containing 500 mg of daptomycin

    Read More
  • Dr. Reddy's Lab launches Testosterone Gel
    6th May 2019, 10:31 AM

    Dr. Raddy's Testosterone Gel 1.62% (20.25 mg/1.25 g pump actuation) is available in a net quantity of 88 g pump which dispenses 20.25 mg of testosterone per actuation

    Read More
  • Dr Reddy's starts recall of anti-seizure drug in US market: Report
    26th Apr 2019, 15:16 PM

    The company has started recalling of Divalproex 100-count and 500-count bottles, totaling 33,958 bottles on April 11, 2019

    Read More
  • Dr Reddy's gets nod for anti-platelet drug in China
    26th Apr 2019, 10:34 AM

    The company believes that the sales from this product will not be material in FY20

    Read More
  • Dr. Reddys Lab receives EIR from USFDA for Formulations Plant 3 in Hyderabad
    16th Apr 2019, 08:57 AM

    This site had undergone an audit by the USFDA, wherein the company were issued a Form 483

    Read More
  • Dr. Reddy's Lab to acquire portfolio of 42 ANDAs in US
    15th Apr 2019, 09:54 AM

    The portfolio includes more than 30 generic injectable products

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.